Integral Diagnostics Past Earnings Performance

Past criteria checks 0/6

Integral Diagnostics's earnings have been declining at an average annual rate of -24.6%, while the Healthcare industry saw earnings growing at 1.5% annually. Revenues have been growing at an average rate of 14.9% per year.

Key information

-24.6%

Earnings growth rate

-28.4%

EPS growth rate

Healthcare Industry Growth	2.4%
Revenue growth rate	14.9%
Return on equity	-19.3%
Net Margin	-12.7%
Next Earnings Update	27 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Integral Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CHIA:IDX Revenue, expenses and earnings (AUD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	456	-58	26
30 Sep 23	449	-16	26
30 Jun 23	441	25	25
31 Mar 23	418	23	24
31 Dec 22	395	21	22
30 Sep 22	378	18	21
30 Jun 22	361	15	21
31 Mar 22	361	18	21
31 Dec 21	360	22	22
30 Sep 21	356	26	22
30 Jun 21	351	31	22
31 Mar 21	333	32	21
31 Dec 20	315	32	19
30 Sep 20	295	28	18
30 Jun 20	276	23	16
31 Mar 20	263	22	18
31 Dec 19	250	21	19
30 Sep 19	241	21	21
30 Jun 19	232	21	24
31 Mar 19	222	19	23
31 Dec 18	211	17	23
30 Sep 18	200	16	22
30 Jun 18	189	15	21
31 Mar 18	187	15	21
31 Dec 17	185	15	20
30 Sep 17	182	15	20
30 Jun 17	180	15	20
31 Mar 17	177	16	19
31 Dec 16	175	16	19
30 Sep 16	171	14	18
30 Jun 16	168	11	18
31 Mar 16	165	11	17
31 Dec 15	162	11	17
30 Sep 15	157	8	17
30 Jun 15	151	5	16
30 Jun 14	4	3	1
30 Jun 13	3	3	0

Quality Earnings: IDX is currently unprofitable.

Growing Profit Margin: IDX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IDX is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare IDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-19.1%).

Return on Equity

High ROE: IDX has a negative Return on Equity (-19.26%), as it is currently unprofitable.

Integral Diagnostics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Full year 2022 earnings released

Recent updates

First half dividend of AU$0.025 announced

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Integral Diagnostics Limited Announces Board Changes

Upcoming dividend of AU$0.025 per share at 2.0% yield

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Independent Non-Executive Director recently bought AU$114k worth of stock

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Now 21% undervalued after recent price drop

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Executive Director recently bought AU$70k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

Executive Director has left the company

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations

Integral Diagnostics Limited Announces Retirement of Dr. Chien Ho as Executive Director, Effective on March 1, 2021

Integral Diagnostics Limited to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: AU$4.48

New 90-day high: AU$4.42

Executive Director recently sold AU$266k worth of stock

Executive Director recently sold AU$123k worth of stock

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million.

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited.

New 90-day high - AU$4.30

Earnings released

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta